Market Update: AbbVie Inc (NYSE:ABBV) – U.S. FDA approves AbbVie all-oral hepatitis C treatment

[Reuters] – U.S. health regulators on Friday approved AbbVie’s all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. … Read more . . . → Read More: Market Update: AbbVie Inc (NYSE:ABBV) – U.S. FDA approves AbbVie all-oral hepatitis C treatment Similar Articles: Stock Update: AbbVie Inc (NYSE:ABBV) – Europe gives green light to AbbVie hepatitis C medicine, others Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment